Previous 10 | Next 10 |
GD Culture Group Limited (GDC) is expected to report for Q4 2023 Citizens Inc. Class A ($1.00 Par) (CIA) is expected to report for quarter end 2023-12-31 Escalade Incorporated (ESCA) is expected to report for Q4 2023 Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31...
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced a webcast/conference call in conjunction with its fourth quarter and year end 2023 update and financial results for Monday, April 1 at 4:30 p.m. ET. To participate in the webcast, please use the following registration link: http...
X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...
AIA Group Limited ADR (AAGIY) is expected to report for Q4 2023 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 SecureWorks Corp. (SCWX) is expected to report $-0.15 for Q4 2024 Acacia Research Corporation (ACTG) is expected to report for quarter end...
2024-03-09 07:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-02-17 01:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-26 11:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-11 08:15:15 ET More on Acorda Therapeutics Acorda Therapeutics, Inc. (ACOR) Q3 2023 Earnings Call Transcript Acorda Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Acorda Therapeutics GAAP EPS of -$7.16, revenue of $27.72M Financial ...
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced it will regain global commercialization rights to FAMPYRA ® (fampridine) following a decision by Biogen to terminate the license and collaboration agreement between the companies, effective January 1, 2025. FAMPYRA is indicated in ...
2023-11-13 17:43:09 ET Acorda Therapeutics, Inc. (ACOR) Q3 2023 Earnings Conference Call November 13, 2023, 04:30 PM ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - Founder, CEO, President & Director Michael Gesser - CFO ...
News, Short Squeeze, Breakout and More Instantly...
Acorda Therapeutics Inc. Company Name:
ACOR Stock Symbol:
NASDAQ Market:
Acorda Therapeutics Inc. Website:
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial resul...
Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collaboration with Jo...
A look at the top 10 most actives in the United States Verb Technology Company Inc. (VERB) rose 11.3% to $0.2025 on volume of 40,515,259 shares Rallybio Corporation (RLYB) rose 80.4% to $2.9401 on volume of 39,492,767 shares Trio Petroleum Corp. (TPET) rose 36.3% to $0.2499 on volume of 3...